• OncoSec Medical Inc., of San Diego, received Investigational Review Board (IRB) approval at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center for a Phase II trial evaluating OncoSec's OMS ElectroImmunotherapy to treat cutaneous T-cell lymphoma.